WithdrawnNot Applicable

Reduction of BK Viremia in Kidney Transplant Patients

Stopped: No participants enrolled due to logistical issues related to COVID-19 with recruiting patients.

Germany0Started 2022-02-01

Plain-language summary

Reduction of BK Viremia by treating kidney transplant patients.

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Subject is currently participating in another clinical investigation
✕. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
✕. Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
✕. Have Child-Pugh Class C cirrhosis
✕. Have platelet count \<30.000/uL
✕. Contraindications for heparin sodium for injection
✕. Subjects demonstrating any contraindication for this treatment as described in the IFU
✕. Patients without existing hemodialysis access

Change in log 10 viral load

Timeframe: At day 0 and the following 3 treatments within five days after beginning with the first treatment.

NCT IDNCT04984902

SponsorExThera Medical Europe BV

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-02-01